Do not discontinue taking entecavir without your doctor’s advice.
Entecavir should be taken on an empty stomach. Please follow the instructions of your doctor.
Do consult your doctor before taking entecavir, if you are pregnant or planning to become pregnant.
Do consult your doctor before taking entecavir, if you are breast-feeding.
Do not drive or operate machines if you feed dizzy, tired or sleepy after taking entecavir.
Do consult your doctor before taking entecavir if you have Kidney disease, any other liver disease or a liver transplant.
Consult your doctor before taking entecavir, if you have AIDS or HIV (human immunodeficiency virus) infection. Tests for HIV should be performed before taking entecavir in suspected individuals.
Inform your doctor, if you have taken medicines containing active drug lamivudine (Epivir, Epzicom, Trizivir) or telbivudine. Inform your doctor about all medications you have received in the past for treatment of hepatitis B.
Worsening of hepatitis B may occur while taking entecavir and upon discontinuation. Liver function tests must be conducted while on treatment and upon discontinuation.
Immediately report symptoms such as nausea, vomiting and stomach pain to your doctor. These might indicate development of a life-threatening side effect of entecavir called lactic acidosis (excess lactic acid in blood). Lactic acidosis occurs more often in women, particularly if they are very overweight.
Interaction with alcohol is unknown. Please consult your doctor.
WEIGH RISKS VS BENEFITS
Baraclude 0.5mg Tablet may be unsafe to use during pregnancy.
Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor.
Baraclude 0.5mg Tablet is probably unsafe to use during lact
Limited human data suggest that the drug could represent a significant risk to the baby.
Baraclude 0.5mg Tablet may make you feel dizzy, sleepy, tire
d, or decrease alertness. If this happens, do not drive.
Baraclude 0.5mg Tablet should be used with caution in patien
ts with kidney disease. Dose adjustment of Baraclude 0.5mg Tablet may be needed. Please consult your doctor.
Baraclude 0.5mg Tablet is safe to use in patients with liver
disease. No dose adjustment of Baraclude 0.5mg Tablet is recommended.
What were the side-effects while using this medicine?
No Side Effect
How do you take this medicine?
With or without food
How much was the improvement?
Please rate this medicine on price?
What are you using this medicine for?
Chronic hepatitis B virus (HBV) infection
Survey Participants: 21
“The following are the results of on-going survey on 1mg.com for Baraclude 0.5mg Tablet. These results only indicate the perceptions of the website users. Please base your medical decisions only on the advice of a doctor or a registered medical professional.”
Baraclude monohydrate is the salt form of active drug Baraclude which is used in the preparation of different formulations (eg. Tablets). It has the same antiviral activity like Baraclude and is used to treat long-term infection of the liver (hepatitis) caused by hepatitis B virus
Baraclude is a trade name for active drug Baraclude and is used to treat long-term infection of the liver (hepatitis) caused by hepatitis B virus. It is effective if used as advised by your doctor. The effectiveness of Baraclude may vary depending upon individual cases
Q. What are the side effects of baraclude?
Baraclude is a trade name for active drug entecavir and has the same side effects as entecavir
Q. How does baraclude work?
Baraclude is a trade name for active drug entecavir. Entecavir is an antiviral drug and works by blocking the DNA synthesis in hepatitis B virus, a process essential for the virus to grow and multiply. It stops the virus from spreading in the body
Baraclude is an antiviral drug used to treat long-term infection of the liver (hepatitis) caused by hepatitis B virus. It is effective if used as advised by your doctor. The effectiveness and duration of treatment may vary upon individual response